EGF 105084, a phase II study of lapatinib for brain metastases in patients (pts) with HER2+ breast cancer following trastuzumab (T) based systemic therapy and cranial radiotherapy (RT)
EGF 105084, a phase II study of lapatinib for brain metastases in patients (pts) with HER2+ breast cancer following trastuzumab (T) based systemic therapy and cranial radiotherapy (RT). J Clin Oncol. 2007; 25(18S):abstract 1012.